Patient-Derived Models

Explore the utility of patient-derived models, including organoids, patient-derived xenografts (PDX), and patient-derived tumor organoids (PDTO), for studying cancer stem cell biology and drug screening. This track highlights the advantages and limitations of different patient-derived model systems, offering insights into their relevance for understanding tumor heterogeneity, drug response, and therapeutic resistance. Discover how patient-derived models are shaping preclinical drug development and personalized medicine approaches in oncology, offering new opportunities for translational research and therapeutic innovation.

    Related Conference of Patient-Derived Models

    June 10-11, 2024

    8th Global Meeting on Oncology and Radiology

    Barcelona, Spain
    July 11-12, 2024

    24th World Congress on Cancer and Diagnostics

    Vancouver, Canada
    July 18-19, 2024

    14th World Congress on Breast Cancer

    Paris, France
    September 16-17, 2024

    9th World Conference on Breast and Cervical Cancer

    London, UK
    September 19-20, 2024

    25th World Congress on Cancer Summit

    Paris, France
    November 24-25, 2024

    7th International Conference on Anti-Cancer Drugs

    Vancouver, Canada

    Patient-Derived Models Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in